Lexicon Pharmaceuticals Gets a Buy Rating from Wedbush

Wedbush analyst Liana Moussatos reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX) yesterday and set a price target of $42. The company’s shares closed yesterday at $10.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.1% and a 44.3% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.

Lexicon Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $40.

See today’s analyst top recommended stocks >>

The company has a one-year high of $18 and a one-year low of $7.67. Currently, Lexicon Pharmaceuticals has an average volume of 581.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It also offers programs in clinical development for diabetes, irritable bowel syndrome, and carcinoid syndrome.